Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer hands Bosulif Phase III to venture-backed drug developer

This article was originally published in Scrip

Executive Summary

Pfizer has signed a late-stage clinical development deal with venture-backed drug developer Avillion, to carry out a Phase III trial for cancer drug Bosulif in order to expand the drug's indication to include first-line treatment for chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). While the need to seek the services of a start-up company in developing its drug might be seen as an embarrassment for more pharma companies with more machismo, Pfizer sees the deal as a way of more rapidly exploiting the potential of Bosulif.

You may also be interested in...



What Does AI Excellence Look Like In Big Pharma?

Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.

Nurturing The Next Generation Of Top Talent

Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative. 

30 Life Sciences Leaders In The Spotlight

In this first edition of In Vivo's ‘Rising Leaders’ list, the focus is on entrepreneurs and innovators who represent the next wave of creativity in health care. 

Topics

Related Companies

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel